Chenhui Cao

Dr. Chenhui Cao


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
HWHong Wu
Hong Wu
XLXuefeng Leng
Xuefeng Leng
QLQianshi Liu
Qianshi Liu
TMTianqin Mao
Tianqin Mao
Tao JiangTao Jiang
Tao Jiang
CXChuan Xu
Chuan Xu
Neoadjuvant chemoimmunotherapy (NACI) has shown promise in the treatment of resectable esophageal squamous cell carcinoma (ESCC). The microbiomes of patients can impact therapy response, and previous studies have demonstrated that intestinal microbiota influences cancer immunotherapy by activating gut immunity. Here, we investigated the effects of intratumoral microbiota on the response of patients with ESCC to NACI. Intratumoral microbiota signatures of β-diversity were disparate and predicted the treatment efficiency of NACI. The enrichment of Streptococcus positively correlated with GrzB+ and CD8+ T-cell infiltration in tumor tissues. The abundance of Streptococcus could predict prolonged disease-free survival in ESCC. Single-cell RNA sequencing demonstrated that responders displayed a higher proportion of CD8+ effector memory T cells but a lower proportion of CD4+ regulatory T cells. Mice that underwent fecal microbial transplantation or intestinal colonization with Streptococcus from responders showed enrichment of Streptococcus in tumor tissues, elevated tumor-infiltrating CD8+ T cells, and a favorable response to anti-PD-1 treatment. Collectively, this study suggests that intratumoral Streptococcus signatures could predict NACI response and sheds light on the potential clinical utility of intratumoral microbiota for cancer immunotherapy. Significance: Analysis of intratumoral microbiota in patients with esophageal cancer identifies a microbiota signature that is associated with chemoimmunotherapy response and reveals that Streptococcus induces a favorable response by stimulating CD8+ T-cell infiltration. See related commentary by Sfanos, p. 2985

7 June 2024 in Science Advances
Verified
Journal Article
Open access
HWHong Wu
Hong Wu
YLYiqiang Liu
Yiqiang Liu
QLQianshi Liu
Qianshi Liu
ZLZhaoshen Li
Zhaoshen Li
YWYejian Wan
Yejian Wan
CXChuan Xu
Chuan Xu
Hepatocellular carcinoma (HCC) acquires an immunosuppressive microenvironment, leading to unbeneficial therapeutic outcomes. Hyaluronan-mediated motility receptor (HMMR) plays a crucial role in tumor progression. Here, we found that aberrant expression of HMMR could be a predictive biomarker for the immune suppressive microenvironment of HCC, but the mechanism remains unclear. We established an HMMR −/− liver cancer mouse model to elucidate the HMMR-mediated mechanism of the dysregulated “don't eat me” signal. HMMR knockout inhibited liver cancer growth and induced phagocytosis. HMMR high liver cancer cells escaped from phagocytosis via sustaining CD47 signaling. Patients with HMMR high CD47 high expression showed a worse prognosis than those with HMMR low CD47 low expression. HMMR formed a complex with FAK/SRC in the cytoplasm to activate NF-κB signaling, which could be independent of membrane interaction with CD44. Notably, targeting HMMR could enhance anti–PD-1 treatment efficiency by recruiting CD8 + T cells. Overall, our data revealed a regulatory mechanism of the “don't eat me” signal and knockdown of HMMR for enhancing anti–PD-1 treatment.

23 November 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LZLinlin Zheng
Linlin Zheng
QYQi yang
Qi yang
菲李菲菲 李
菲菲 李
MZMin Zhu
Min Zhu
HYHaochi Yang
Haochi Yang
CCChenhui Cao
Chenhui Cao
Tumor therapies have entered the immunotherapy era. Immune checkpoint inhibitors have achieved tremendous success, with some patients achieving long-term tumor control. Tumors, on the other hand, can still accomplish immune evasion, which is aided by immune checkpoints. The majority of immune checkpoints are membrane glycoproteins, and abnormal tumor glycosylation may alter how the immune system perceives tumors, affecting the body’s anti-tumor immunity. Furthermore, RNA can also be glycosylated, and GlycoRNA is important to the immune system. Glycosylation has emerged as a new hallmark of tumors, with glycosylation being considered a potential therapeutic approach. The glycosylation modification of immune checkpoints and the most recent advances in glycosylation-targeted immunotherapy are discussed in this review.

7 June 2024 in Journal of Natural Medicines
Verified
Journal Article
Open access
PDF file
HYHaochi Yang
Haochi Yang
BWBinghuo Wu
Binghuo Wu
QYQi Yang
Qi Yang
TTTian Tan
Tian Tan
DSDan Shang
Dan Shang
CXChuan Xu
Chuan Xu
Urolithin families are gut-microbial metabolites of ellagic acid (EA). Although urolithin A (UA) and urolithin B (UB) were reported to have antiproliferative activities in cancer cells, the role and related mechanisms of urolithin C (UC) in colorectal cancer (CRC) have not yet been clarified. In this study, we assess the antitumor activities of UC in vitro and in vivo and further explore the underlying mechanisms in CRC cell lines. We found that UC inhibited the proliferation and migration of CRC cells, induced apoptosis, and arrested the cell cycle at the G2/M phase in vitro, and UC inhibited tumor growth in a subcutaneous transplantation tumor model in vivo. Mechanically, UC blocked the activation of the AKT/mTOR signaling pathway by decreasing the expression of Y-box binding protein 1(YBX1). The AKT agonist SC79 could reverse the suppression of cell proliferation in UC-treated CRC cells. In conclusion, our research revealed that UC could prevent the progression of CRC by blocking AKT/mTOR signaling, suggesting that it may have potential therapeutic values. Graphical Abstract

9 September 2025 in Annals of Medicine
Verified
Journal Article
Open access
BWBinghuo Wu
Binghuo Wu
FSFei Song
Fei Song
XHXue Han
Xue Han
MZMinyi Zhao
Minyi Zhao
MHMeijia Huang
Meijia Huang
SCSongtao Cheng
Songtao Cheng
This study provides a comprehensive analysis of the global, regional, and national epidemiology of acute myeloid leukemia (AML) from 1990 to 2021, focusing on incidence, mortality, and disability-adjusted life years (DALYs). Using data from the Global Burden of Disease (GBD) study, we investigated the trends and patterns of AML across 204 countries and territories during 1990 to 2021. All statistical analyses and data visualizations were performed using R (version 4.4.2) and JD_GBDR (V2.36). The global incidence of AML increased by 82.25% from 79.37 × 10³ cases in 1990 to 144.65 × 10³ cases in 2021, with significant variations across regions. AML-related deaths increased by 73.77% globally, from 74.92 × 10³ in 1990 to 130.19 × 10³ in 2021. DALYs rose by 23.70%, from 3342.91 × 10³ in 1990 to 4135.06 × 10³ in 2021. High SDI regions face higher incidence and mortality due to advanced diagnostics and aging, while low-middle SDI regions show rapid increases likely due to urbanization and lifestyle changes. Addressing these disparities requires improved healthcare infrastructure, early detection, and targeted interventions, particularly in low- and middle-income countries (LMICs).

24 November 2025 in Chinese Medical Journal
Verified
Journal Article
Open access
DSDan Shang
Dan Shang
LZLinlin Zheng
Linlin Zheng
JCJie Chen
Jie Chen
TTTian Tan
Tian Tan
MYMaojin Yao
Maojin Yao
CXChuan Xu
Chuan Xu
Ferroptosis is an iron-catalyzed form of regulated cell death mediated by lipid peroxidation. Novel ferroptosis-based therapeutic strategies could selectively target core pathways associated with the proliferation and survival of malignant tumors, not only directly inducing tumor cell death but also overcoming resistance to conventional therapies, paving a new path for precision cancer treatment. Ferroptosis suppresses tumor progression through lethal lipid peroxidation, yet is co-opted by cancers through antioxidant adaptations. This review highlights the dual role of ferroptosis in tumor biology and explores the dynamic interplay between ferroptosis and the tumor microenvironment to modulate both immunogenic cell death and immunosuppressive signaling. We discuss the therapeutic potential of ferroptosis induction through synergistic integration with chemotherapy, targeted therapy, radiotherapy, hyperthermia therapy, and immunotherapy to simultaneously suppress tumor progression, overcome resistance mechanisms, and potentiate antitumor immunity, thereby offering innovative strategies to address treatment-refractory malignancies. Challenges include identifying predictive biomarkers, developing tumor-selective ferroptosis inducers, and modulating ferroptosis–immune interactions within the tumor microenvironment. By addressing these issues, ferroptosis has the potential to overcome treatment-resistant and immune-evasive tumors, reshaping oncology therapeutics.